GlassScriptPhysician profile
Harjit Bajaj
NPI 1811977051
$25,389.36
in general payments reported to CMS, 2019-2025
62 companies · $4,254 in 2025
The $4,254 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,021 · 2020: $2,354 · 2021: $3,458 · 2022: $4,310 · 2023: $4,281 · 2024: $4,712 · 2025: $4,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,036.75 |
| Education | $209.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,581.71 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $2,391.43 | 2021-2025 | Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $1,703.85 | 2020-2025 | |
| Ucb, INC. | $1,552.36 | 2019-2025 | Briviact, Zilbrysq, Nayzilam |
| Biogen, INC. | $1,385.83 | 2019-2024 | Vumerity, Avonex, Plegridy |
| Emd Serono, INC. | $1,078.60 | 2019-2025 | Mavenclad, Mavenclad |
| Eisai INC. | $1,000.98 | 2019-2025 | |
| Pfizer INC. | $825.50 | 2021-2025 | |
| Argenx US, INC. | $785.15 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurelis, INC. | $768.25 | 2020-2025 | Valtoco |
| Celgene Corporation | $691.44 | 2021-2025 | Zeposia |
| Sumitomo Pharma America, INC. | $611.15 | 2023-2024 | Aptiom |
| Alexion Pharmaceuticals, INC. | $598.75 | 2019-2025 | Ultomiris, Soliris |
| Janssen Pharmaceuticals, INC | $557.19 | 2020-2022 | |
| Banner Life Sciences, LLC | $535.26 | 2021-2024 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $485.74 | 2021-2025 | Vyepti |
| Csl Behring | $467.59 | 2020-2025 | Hizentra |
| Acadia Pharmaceuticals INC | $452.65 | 2019-2025 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $452.06 | 2021 | |
| Tanabe Pharma America, INC. | $392.82 | 2019-2025 | Radicava |
| Mallinckrodt Hospital Products INC. | $388.09 | 2020-2025 | Acthar |
| Sk Life Science, INC. | $380.78 | 2022-2025 | Xcopri |
| Allergan, INC. | $378.58 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $362.65 | 2019-2025 | Ingrezza |
| Amgen INC. | $353.38 | 2020-2025 | Uplizna |
| Jazz Pharmaceuticals INC. | $314.14 | 2022-2024 | Epidiolex |
| Biohaven Pharmaceutical Holding Company LTD. | $299.06 | 2022 | |
| Vanda Pharmaceuticals INC. | $243.29 | 2024-2025 | Ponvory |
| Grifols USA, LLC | $240.72 | 2019-2025 | Gamunex-C |
| Avanir Pharmaceuticals, INC. | $227.06 | 2019-2022 | |
| Organon LLC | $222.35 | 2024 | |
| Genentech USA, INC. | $216.83 | 2022-2025 | Ocrevus |
| Lilly USA, LLC | $213.37 | 2019-2025 | Reyvow, Emgality, Amyvid |
| Janssen Biotech, INC. | $210.65 | 2025 | |
| Genzyme Corporation | $193.65 | 2019-2025 | |
| Greenwich Biosciences, INC. | $166.21 | 2019 | |
| Adamas Pharmaceuticals, INC. | $163.04 | 2019-2021 | |
| Catalyst Pharmaceuticals, INC. | $135.63 | 2020-2024 | Fycompa |
| Sunovion Pharmaceuticals INC. | $125.00 | 2022 | |
| Amneal Pharmaceuticals LLC | $97.75 | 2022-2025 | Rytary, Crexont |
| Mallinckrodt Enterprises LLC | $95.07 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.01 | 2023-2024 | Hyqvia |
| Horizon Therapeutics Plc | $92.89 | 2021-2023 | Uplizna |
| Otsuka America Pharmaceutical, INC. | $91.82 | 2023 | Nuedexta, Rexulti |
| Arbor Pharmaceuticals, INC. | $85.24 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $81.53 | 2019-2022 | |
| Cycle Pharmaceuticals INC | $76.24 | 2025 | Bafiertam, Tascenso Odt |
| Bayer Healthcare Pharmaceuticals INC. | $58.95 | 2019 | |
| Mdd US Operations, LLC | $55.32 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $51.16 | 2020 | |
| Sanofi-Aventis U.S. LLC | $43.76 | 2019-2020 | |
| Nevro Corp. | $40.32 | 2022-2024 | Senza |
| Akcea Therapeutics, INC. | $39.03 | 2020 | |
| Acorda Therapeutics, INC | $37.79 | 2021-2023 | Inbrija, Ampyra |
| Azurity Pharmaceuticals, INC. | $37.23 | 2024-2025 | Horizant |
| Tg Therapeutics, INC. | $35.13 | 2023 | |
| Currax Pharmaceuticals LLC | $30.40 | 2023-2024 | Onzetra Xsail, Contrave |
| Kyowa Kirin, INC. | $20.96 | 2024 | Nourianz |
| Alnylam Pharmaceuticals INC. | $20.50 | 2021 | |
| Livanova USA, INC. | $18.78 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Medtronic, INC. | $17.53 | 2021 | |
| Avion Pharmaceuticals | $15.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harjit Bajaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.